Dexcom INC Form 4 insider transactions

Nicholas Augustinos, a Director of Dexcom Inc, reported a transaction in 1,075 shares of common stock on August 12, 2026.

Bridgette P Heller, a Director of Dexcom Inc, sold 1,012 shares of common stock on August 12, 2026 for $88.29 per share.

Mark G Foletta, a Director of Dexcom Inc, sold 4,000 shares of common stock on July 31, 2026.

Kevin R Sayer, Executive Chair and a Director of Dexcom Inc, sold 26,756 shares of common stock on July 20, 2026 for $76.32 per share.

Michael Jon Brown, EVP Chief Legal Compliance Off of Dexcom Inc, sold 1,700 shares of common stock on July 15, 2026 for $74.42 per share.

Dexcom Executive Chair Kevin R. Sayer sold 26,756 shares of common stock for $72 per share under a pre-arranged 10b5-1 trading plan.

DexCom Inc. reports that Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of common stock on June 15, 2026, as part of a pre-arranged 10b5-1 trading plan.

DexCom Director Mark G. Foletta sold a total of 6,530 shares of common stock through his family trust, executing trades under a pre-arranged 10b5-1 plan.

EVP and Chief Commercial Officer Jon Coleman sold 9,823 shares of DexCom common stock under a pre-arranged 10b5-1 trading plan.

Director Steven R. Altman was granted 5,565 restricted stock units as part of his equity compensation package.

DexCom, Inc. director Kyle Malady was granted 5,575 restricted stock units as part of standard equity compensation.

DexCom, Inc. director Nicholas Augustinos was granted 5,575 restricted stock units as part of his equity compensation.

DexCom, Inc. director Mark G. Foletta was granted 6,331 restricted stock units as part of standard equity compensation.

DexCom, Inc. director Bridgette P. Heller was granted 5,575 restricted stock units as part of an equity compensation award.

DexCom Director Albert Frederick Osterloh IV was granted 1,630 restricted stock units as part of his annual compensation.

DexCom Director Rimma Driscoll was granted 5,605 restricted stock units as part of her annual equity compensation.

DexCom Director Euan Ashley was granted 5,565 restricted stock units as part of his annual equity compensation.

DexCom Director Richard Alexander Collins was granted 5,605 restricted stock units as part of his compensation.

Director Renee D. Gala was granted 5,605 restricted stock units as part of her equity compensation at DexCom, Inc.

Jacob Steven Leach, President, CEO, and Director of DEXCOM INC, reported a transaction involving common stock on May 22, 2026.

Michael Jon Brown, EVP Chief Legal Compliance Officer at DexCom Inc., reported a transaction involving common stock on May 22, 2026.

Dexcom Inc. EVP and CFO Jereme M. Sylvain reported a transaction involving the withholding of shares for tax obligations and disclosed beneficial ownership details.

Sadie Stern, EVP Chief People & Culture Officer at DexCom Inc., reported a transaction involving common stock, with shares withheld for tax obligations.

Dexcom Executive Chair Kevin R. Sayer sold 26,759 shares of common stock for $72 per share under a pre-arranged 10b5-1 trading plan.

DexCom Inc. reports that EVP Michael Jon Brown sold 1,700 shares of common stock on May 15, 2026, as part of a pre-arranged 10b5-1 trading plan.

Director Bridgette P. Heller of Dexcom Inc. has sold 1,012 shares of common stock for $60.01 per share under a pre-arranged 10b5-1 trading plan.

DexCom director Nicholas Augustinos transferred 5,046 shares of common stock into a revocable trust.

Director Richard Alexander Collins transferred 5,074 shares of DexCom common stock into his revocable trust.

DexCom Director Mark G. Foletta transferred 5,731 shares of common stock from direct ownership to a family trust.

DexCom Director Steven R. Altman transferred 5,037 shares of common stock into his family trust.